The statement that is NOT true is option (b): "Treatment is similar to that of polymyalgia rheumatica"
Giant cell arteritis requires significantly more aggressive treatment than polymyalgia rheumatica, making option (b) the incorrect statement. While both conditions may overlap and share glucocorticoid use, the treatment intensity, urgency, and approach differ substantially.
Why Option (b) is NOT True
Treatment Differences
GCA requires urgent, high-dose glucocorticoid therapy (40-60 mg/day prednisolone) to prevent irreversible ischemic complications, particularly vision loss 12. In contrast, PMR typically responds to much lower glucocorticoid doses (12.5-25 mg/day).
The 2021 ACR/Vasculitis Foundation guidelines emphasize that GCA management focuses on preventing tissue ischemia and vascular damage, requiring immediate high-dose steroids upon clinical suspicion 1. The 2024 treat-to-target recommendations further distinguish that GCA requires "urgent treatment to avoid ischaemic complications," while PMR management primarily aims at maximizing quality of life without the same urgency 33.
Additionally, tocilizumab is FDA-approved for GCA but not yet approved for PMR, despite showing efficacy in both conditions 3. This reflects the different treatment paradigms and regulatory recognition of disease severity.
Why the Other Options ARE True
Option (a): Co-occurrence with PMR - TRUE
GCA and PMR are "overlapping inflammatory rheumatic conditions" with frequent co-occurrence 33. The conditions share pathophysiologic features and often present together.
Option (c): Cause of Fever of Unknown Origin - TRUE
GCA commonly presents with systemic symptoms including fever 145. Constitutional symptoms and fever are well-recognized manifestations that can lead to presentation as fever of unknown origin.
Option (d): Pain During Chewing (Jaw Claudication) - TRUE
Jaw claudication is a highly specific finding for GCA 456. It results from ischemia of the masseter muscles due to involvement of the maxillary artery and is considered one of the most specific clinical features for diagnosis.
Option (e): Irreversible Blindness - TRUE
Vision loss in GCA, when it occurs, is usually permanent 5. The guidelines emphasize urgent treatment specifically to prevent this irreversible complication 13. Studies confirm that despite treatment, visual loss that has already occurred typically does not recover, underscoring the critical importance of early diagnosis and immediate high-dose glucocorticoid therapy.
Clinical Pitfall
The key error would be treating suspected GCA with the lower glucocorticoid doses appropriate for PMR alone. Even when the conditions overlap, the presence of cranial symptoms or risk of ischemic complications mandates GCA-level treatment intensity (40-60 mg prednisolone daily) rather than PMR-level dosing 2.